Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hear ya chances... they need to get their act together like earlier this year... they've been making some mistakes lately with handling PRs...
exactly chances... hopefully at least 2.5 million but I'm a little worried it won't be that good... but at least they exceeded 2 million...
chances, chances, chances... calm down my friend... we were referring to this post where you ask "is it time to sell?" It was a bit confusing as to what you meant... it seems you were asking if it is time to sell SWME... why you thought it's time to sell I dunno... I don't know what you're talking about Dr Laura and the NFA... there was no mention of that...
http://www.investorshub.com/boards/read_msg.asp?message_id=8813859
And don't worry.. I care very much... I have over 200k shares and I'm down 60%... stupid me... I have a lot to care about with SWME... most of what I had is down the toilet... that's what I get for thinking I could do good research, buy early on an up and coming company, and do well for myself and my family... oh well... as the old saying goes... money can't buy happiness... hopefully I can make it back someday, somehow....
Thanks again chances... it's good news that they have a system like this in place now... it cuts down on administrative costs and companies like Wal-Mart won't even do business with you unless you can exchange EDI data with them...
Ah ok... interesting... thanks! Is it this redtail? I could see how they could have problems without a system like this in place... most companies want to exchange EDI data as much as possible...
http://www.redtailsolutions.com/site/content/about_us/about_us.asp
I think they'll beat 2 million as well... 2.5 would be great and 3.0 whould really get the share price going... that's what we need... I don't think anything but good numbers will do much for the share price...
No I sure didn't... I did a quick search on google and couldn't find anything... what is the redtail article?
Did look at MCU a bit and they look pretty good... I would caution however, I've seen plenty of drugs look good in phase two only to fail in phase three... I see they're offering some shares today... not a bad idea to shore up the account at these prices... I'll keep them on my watch list and perhaps buy in when they're on sale... thanks :)
excellent chances... thanks... I'll try to find some time to research this weekend and let you know what I think :)
chances... thanks... will check it out... I don't think it's time to sell here... in fact, it looks like the perfect time to buy... 4Q numbers should be real strong imo...
hi chances... I just tried it and it worked fine for me... I requested some 024 Fibro... perhaps you have some security settings in your browser that causing problems...
exactly chances... it's obvious we won't get a nice move until revenues demonstrate the growth potential... I don't expect an update this month but I would expect an "estimate" of the Q4 revenues in early January if they are especially good... hopefully the numbers are very good... 2.5-3.0 million and EBITDA positive should get some serious interest in the shares... that should indicate serious profitability will happen in 2006... add very high growth rate with high margins and low debt and it could be an explosive move... the kind that people look at and say, man I wish I was in early on that... hopefully we'll be one of the ones that get to say, "we were"! lol
oh yea... that's today... good one... thanks!
chances... really... what? i haven't heard anything about it... thanks
yea but we haven't heard anything since on that product... also, they licensed PMS Escape since that time which makes me think that Ayala is out of the picture for whatever reason...
damn chances... that would justify a share price in the dollars in my opinion... I think we'll get there... it's just a matter of when... we'll see one million per month sales volumes, I'm sure of it... probably not until 2007 or later is my guess...
Swiss Medica coming soon to the EU!
www.swissmedica.de
My pleasure my friend... I am very much looking forward to .50+ a share so we all are sitting on nice profits and laughing about these tough times... our patience will be rewarded... I'm sure!
Oh wow... very cool... this kind of stuff will definitely drive people to try the product and I think we all agree that many people who try it like it very much and become regular users... thanks for sharing!
Yea, it seems we need some new buyers and the news to date isn't enough to do it like we need... you and I always said we need a 4-5 million share day... I think it's going to take good earnings to get us going like that... I'm looking for 2.5-3 million for this Q, based on the news I've been seeing... that should get some interest again...
absolutely... I couldn't agree more... better days ahead...
Sounds good to me chances... that seems too optimistic to me but hopefully I'm wrong!
chances, I just spoke with Dave and he told me the reason for the PR yesterday was that response was so much better than expected that they wanted to share it with investors... they sent 46,000 targeted emails and they received 20,000 inquiries in one week... he said this is only the beginning of the campaign and they are very optimistic about the success based on these early results...
no idea chances... could be a little of both I guess...
Swiss Medica's O24 Fibromyalgia Receives Enthusiastic Response to Launch of National Fibromyalgia Association Awareness Campaign
Thursday November 17, 9:31 am ET
TORONTO--(BUSINESS WIRE)--Nov. 17, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) today announced that response to new marketing initiatives has been very strong with over 20,000 requests for samples of O24 Fibromyalgia being received since November 11th. Early demand for O24 Fibromyalgia at the retail level has also been very robust.
O24 Fibromyalgia was featured in a National Fibromyalgia Association news bulletin on November 10 as the first product to receive the Association's Seal of Approval. Since then, Swiss Medica has been contacted not only by thousands of people with the fibromyalgia condition, but by numerous hospitals, clinics and primary care physicians. O24 Fibromyalgia is the first clinically tested product specifically for fibromyalgia to be available in national pharmacies in the United States.
Swiss Medica's President and COO, Grant Johnson says "We have tremendous confidence in the efficacy of both O24 Pain Neutralizer and O24 Fibromyalgia, and we know from experience that if people try the products, the vast majority will experience relief from pain and become loyal users of the product. We are very proud of our strategic alignment with the National Fibromyalgia Association and know that with their support, O24 Fibromyalgia will bring relief to millions of fibromyalgia sufferers across North America."
O24 Fibromyalgia is available at leading retailers, including; Rite Aid, Longs and Albertsons. For detailed store locations, please visit www.024zone.com.
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com,www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.
Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities. Swiss Medica, Inc. (OTC Bulletin Board:SWME - News)
Contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
(866) 485-4243
www.swissmedica.com
OR
Fusion Communications
Media Contact:
Dean Mailey
(604) 218-6767
dean@fusioncom.ca
Wow... excellent information chances... thanks for sharing!
Fibromyalgia in Parade Magazine...
http://www.parade.com/current/columns/fitness.html
chances... I'll post it later... also, I'll check the Sunday paper... I browsed it but I didn't know there was an article to look for... thanks!
Hopefully we have another good week this week! eom
Swiss Medica updated investor guide... very interesting read... taken right from the guide...
Swiss Medica is publicly traded on the NASD OTC Bulletin Board (SWME) and plans to list on the American Stock Exchange (AMEX) by early 2006.
http://www.swissmedica.com/investorguide.pdf
No I sure didn't... I only saw the PMS rasberry... very cool.. thanks!
chances, it looks like we may be on the verge of skyrocketing sales, revenues, and initial profits... EBITDA positive this Q with 3 million in revenues would be spectacular... I think we may come in between 2.5-3 million with all these new developments so early in the Q...
yea man... i'd like to see a little more volume right now but hopefully we'll get some good news soon to kick start that... also, the dvd and promotion for o24 fibro should bring new awareness to the shares as well...
Eckerds, Wal-Mart and Target would make sense... that should get us to the 25k stores by year end as projected...
Sweet! It looks like the sell off is over and a new uptrend is beginning... let's hope... I'm getting a little bit of my massive losses back ;)
Swiss Medica Launches Educational and Sampling Programs for Health Professionals
Business Wire - November 07, 2005 06:00
TORONTO, Nov 07, 2005 (BUSINESS WIRE) -- Swiss Medica, Inc. (OTCBB:SWME) today announced that it has launched a comprehensive educational and sampling program for health professionals including physicians, chiropractors, and pharmacists. The strategy will focus on all three of Swiss Medica's products that are presently available in national drugstores in the United States: O24 Pain Neutralizer, PMS Escape and the newly launched O24 Fibromyalgia.
Swiss Medica's educational program includes:
a) Providing samples and product information at physician continuing medical education conferences.
b) Providing physicians, chiropractors and other health professionals with sampling dispensing units for their offices so that they can offer their patients samples of Swiss Medica's products.
c) Arranging for leading physicians to educate other health professionals about Swiss Medica's safe and effective patented products at medical conferences as well as presenting double-blind studies that highlight the high efficacy of these products.
d) Educating and sampling pharmacists at conferences to educate them on the differentiated and unique attributes of Swiss Medica's products.
e) Direct informational mailers to physicians and other health professionals specializing in the chronic ailments that Swiss Medica's elite products address.
Swiss Medica was present as an exhibitor last week at the American Osteopathic Association national conference in Orlando, Florida. The convention attracted over 6,000 primary care and specialty physicians. There was significant interest in Swiss Medica's elite over-the-counter products and over 600 physicians from across the United States have requested further information on our products and/or sampling units in their medical offices.
Dr. Robert Maurer DO, a senior member of the board of directors of the American Osteopathic College of Rheumatology, after sampling the product personally for a couple of days during the conference in Orlando, was quoted saying " I have had extensive back pain for several months. This product gave me a tremendous amount of relief and comfort. It was easy to apply and with no appreciable side effects. I would highly suggest other pain sufferers try O24 for pain relief."
In addition, Swiss Medica featured its O24 Pain Neutralizer and O24 Fibromyalgia patented, clinically and medically tested all natural products at the American Academy of Pain Management Conference in San Diego in late September and received significant interest in our unique products. We have already shipped over 125 sampling units to physician offices throughout the United States
In addition, the National Fibromyalgia Association will begin in November an integrated communications program with over 10,000 physicians and other health professionals throughout the USA who treat Fibromyalgia. This educational and sampling campaign is being conducted to introduce health professionals to O24 Fibromyalgia, the first clinically-tested product specifically for Fibromyalgia that is available in national pharmacies and the first and only product to receive the National Fibromyalgia Association's Seal of Approval.
"We have found that physicians and other health professionals are eager to learn about Swiss Medica's elite patented over-the-counter alternatives to prescription medications", says Swiss Medica CEO, Raghu Kilambi. "Given the significant side effect concerns with many prescription drugs, health professionals want, more than ever, to offer their patients safe, effective over-the-counter medication for their acute and chronic ailments The response to our products at recent medical conferences and the widespread desire of physicians to offer samples of Swiss Medica's products to their patients is a testament to the growing acceptance of our products by health professionals."
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica is launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia and to order the product online.
Swiss Medica also manufactures PMS Escape(R) which holds US Patent #'s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
Swiss Medica, Inc. (OTC Bulletin Board:SWME)
SOURCE: Swiss Medica, Inc.
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
(866) 485-4243
OR
Fusion Communications
Media Contact:
Dean Mailey
(604) 218-6767
dean@fusioncom.ca
Copyright Business Wire 2005
thanks chances.. it definitely sounds like it's moving there... i'll check back in some of my local as well... o24 fibro should be starting to hit the shelfs... that should drive revenue growth nicely if it happens this q, which it should... cheers!
Technicals looking pretty good here... staying above the 13dma is what we want to see at this stage...
BTW, I meant south and east GA... so like Valdosta and Augusta areas..
I think there is some Rite Aids in GA but not in the Atlanta area... I think they're on the south and/or east side...